Cancer and Leukemia Center’s dedicated team of oncologists, hematology specialists and medical professionals provide evidence-based and personalized care. The individual needs of the patient will determine CLC’s comprehensive and targeted treatments which involve multi-disciplinary approaches and specialist collaboration.
CLC’s board certified doctors are leaders in Beaumont Health System’s Oncology Center of Excellence. Studies show that the outcome in working with a specific disease and planning a successful comprehensive treatment is relative to experience. CLC uses a team approach by coordinating with specialty physicians to successfully treat patients. In the prevention, diagnosis and treatment of patients, CLC uses the best research-proven assessments and targeted therapies in day-to-day client care.
Listening to and providing answers to patient questions is vital to making the best decisions about the plan of care for each individual patient. The CLC team will bring professionalism and experience as well as a sensitive bedside manner to support patients through treatment. Focusing on the individual needs of each patient, CLC treats the patient, not just the disease.
An NCI-led study shows rates for aggressive subtypes of uterine cancer rose rapidly among women ages 30 to 79 from 2000–2015. The findings, published in the Journal of Clinical Oncology, also reveal racial disparities in incidence and survival rates.
A new study provides insight into how cancer immunotherapy works and suggests ways to enhance the treatment’s effectiveness. The NCI-led study, published in Science, examined the effect of high potassium levels on T cells.
The 2019 Szent-Györgyi Prize for Progress in Cancer Research will be awarded to NCI’s Steven A. Rosenberg, M.D., Ph.D., for his pioneering role in the development of immunotherapy.
